XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKHOLDERS EQUITY (Tables)
6 Months Ended
Jun. 30, 2023
STOCKHOLDERS EQUITY  
Schedule of reverse stock split on the basic and diluted net loss per share

 

 

Three

 

 

Three

 

 

Six

 

 

Six

 

 

 

Months Ended

 

 

Months Ended

 

 

Months Ended

 

 

Months Ended

 

Historical per share data – (Pre- Split basis)

 

June 30, 2023

 

 

June 30, 2022

 

 

June 30, 2023

 

 

June 30, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common shareholders

 

$(980,273)

 

$(1,188,760)

 

$(4,799,685)

 

$(5,371,098)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share - basic and diluted

 

$(0.06)

 

$(0.08)

 

$(0.28)

 

$(0.36)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three

 

 

Three

 

 

Six

 

 

Six

 

 

 

Months Ended

 

 

Months Ended

 

 

Months Ended

 

 

Months Ended

 

Historical per share data – (Post- Split basis) (UNAUDITED)

 

June 30, 2023

 

 

June 30, 2022

 

 

June 30, 2023

 

 

June 30, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common shareholders

 

$(980,273)

 

$(1,188,760)

 

$(4,799,685)

 

$(5,371,098)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share - basic and diluted

 

$(0.94)

 

$(1.20)

 

$(4.20)

 

$(5.45)
Schedule of reverse stock split on the condensed consolidated balance sheet

 

 

 

 

 

 

 

 

Pro-Forma Effect

 

 

 

June 30,

 

 

 

 

 

June 30,

 

 

 

2023

 

 

1:15 Adjustment

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$11,202,109

 

 

$-

 

 

$11,202,109

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

9,342,147

 

 

 

-

 

 

 

9,342,147

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity (Deficit):

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, Series D, $0.0001 par value; 2,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

 

-

 

 

 

 

 

 

 

-

 

Preferred stock, Series E, $0.0001 par value; 775,000 shares authorized; 86,000 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

 

9

 

 

 

 

 

 

 

9

 

Preferred stock, Series F, $0.0001 par value; 200,000 shares authorized; 0 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

 

-

 

 

 

 

 

 

 

-

 

Common stock, $0.0001 par value; 100,000,000 shares authorized; 17,792,151 and 16,277,764 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

 

1,780

 

 

 

(1,662)

 

 

118

 

Shares to be issued, 587,945 shares as of March 31, 2023 and December 31, 2022

 

 

-

 

 

 

-

 

 

-

 

Additional paid-in capital

 

 

75,913,399

 

 

 

1,662

 

 

 

75,915,061

 

Accumulated deficit

 

 

(74,055,226)

 

 

 

 

 

 

(74,055,226)

Total stockholders' equity

 

 

1,859,962

 

 

 

-

 

 

 

1,859,962

 

 

 

 

 

 

 

 

 

 

 

 

-

 

Total liabilities and stockholders' equity

 

$11,202,109

 

 

 

-

 

 

$11,202,109

 

 

 

 

 

 

 

Pro-Forma Effect

 

 

 

December 31,

 

 

 

 

December 31,

 

 

 

2022

 

 

1:15 Adjustment

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$14,133,284

 

 

$-

 

 

$14,133,284

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

9,054,967

 

 

 

-

 

 

 

9,054,967

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity (Deficit):

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, Series D, $0.0001 par value; 2,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively

 

 

-

 

 

 

 

 

 

 

-

 

Preferred stock, Series E, $0.0001 par value; 775,000 shares authorized; 86,000 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively

 

 

9

 

 

 

 

 

 

 

9

 

Preferred stock, Series F, $0.0001 par value; 200,000 shares authorized; 0 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively

 

 

-

 

 

 

 

 

 

 

-

 

Common stock, $0.0001 par value; 100,000,000 shares authorized; 16,277,764 and 14,566,420 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively

 

 

1,629

 

 

 

(1,520)

 

 

109

 

Shares to be issued, 587,945 shares as of December 31, 2022 and December 31, 2021

 

 

59

 

 

 

(55)

 

 

4

 

Additional paid-in capital

 

 

74,332,161

 

 

 

1,575

 

 

 

74,333,736

 

Accumulated deficit

 

 

(69,255,541)

 

 

 

 

 

 

(69,255,541)

Total stockholders' equity

 

 

5,078,317

 

 

 

-

 

 

 

5,078,317

 

 

 

 

 

 

 

 

 

 

 

 

-

 

Total liabilities and stockholders' equity

 

$14,133,284

 

 

 

-

 

 

$14,133,284

 

Schedule Of Restricted Stock Grant Activity

 

 

Stock Awards

 

Outstanding at December 31, 2021

 

 

146,000

 

Granted

 

 

95,825

 

Vested

 

 

(88,325 )

Vested and issuable

 

 

(7,500 )

Forfeited or cancelled

 

 

-

 

Outstanding at December 31, 2022

 

 

146,000

 

Granted

 

 

-

 

Vested and issued

 

 

(110,800 )

Vested and issuable

 

 

(35,200)

Outstanding at June 30, 2023

 

 

-